Overexpression of sPRDM16 coupled with loss of p53 induces myeloid leukemias in mice
Open Access
- 21 November 2007
- journal article
- Published by American Society for Clinical Investigation in Journal of Clinical Investigation
- Vol. 117 (12) , 3696-3707
- https://doi.org/10.1172/jci32390
Abstract
Transgenic expression of the abnormal products of acute myeloid leukemia–associated (AML-associated) primary chromosomal translocations in hematopoietic stem/progenitor cells initiates leukemogenesis in mice, yet additional mutations are needed for leukemia development. We report here aberrant expression of PR domain containing 16 (PRDM16) in AML cells with either translocations of 1p36 or normal karyotype. These carried, respectively, relatively high prevalence of mutations in the TP53 tumor suppressor gene and in the nucleophosmin (NPM) gene, which regulates p53. Two protein isoforms are expressed from PRDM16, which differ in the presence or absence of the PR domain. Overexpression of the short isoform, sPRDM16, in mouse bone marrow induced AML with full penetrance, but only in the absence of p53. The mouse leukemias were characterized by multilineage cellular abnormalities and megakaryocyte dysplasia, a common feature of human AMLs with 1p36 translocations or NPM mutations. Overexpression of sPRDM16 increased the pool of HSCs in vivo, and in vitro blocked myeloid differentiation and prolonged progenitor life span. Loss of p53 augmented the effects of sPRDM16 on stem cell number and induced immortalization of progenitors. Thus, overexpression of sPRDM16 induces abnormal growth of stem cells and progenitors and cooperates with disruption of the p53 pathway in the induction of myeloid leukemia.Keywords
This publication has 50 references indexed in Scilit:
- Mutated nucleophosmin detects clonal multilineage involvement in acute myeloid leukemia: impact on WHO classificationBlood, 2006
- Overexpression of PRDM16 in the presence and absence of the RUNX1/PRDM16 fusion gene in myeloid leukemiasGenes, Chromosomes and Cancer, 2006
- Transformation from committed progenitor to leukaemia stem cell initiated by MLL–AF9Nature, 2006
- Identification of truncated RUNX1 and RUNX1-PRDM16 fusion transcripts in a case of t(1;21)(p36;q22)-positive therapy-related AMLLeukemia, 2006
- Delocalization and Destabilization of the Arf Tumor Suppressor by the Leukemia-Associated NPM MutantCancer Research, 2006
- Novel RUNX1‐PRDM16 fusion transcripts in a patient with acute myeloid leukemia showing t(1;21)(p36;q22)Genes, Chromosomes and Cancer, 2005
- P53 and PrognosisNew Insights and Further ComplexityCell, 2005
- P53 and PrognosisCell, 2005
- Low expression of MDS1-EVI1–like-1 (MEL1) and EVI1-like-1 (EL1) genes in favorable-risk acute myeloid leukemiaExperimental Hematology, 2003
- Integrated genomic and epigenomic analyses pinpoint biallelic gene inactivation in tumorsNature Genetics, 2002